Hanyang University · Medicine
Professor Ok-Nam Bae's research lab focuses on the pathophysiology of cerebrovascular and microvascular complications in diabetes, with a particular emphasis on the role of metabolic stress, oxidative stress, and advanced glycation end products such as methylglyoxal in endothelial dysfunction. The lab investigates endogenous protective molecules like carnosine for their neurovascular protective effects, especially in ischemic stroke and diabetic microangiopathy. A key research direction involves identifying novel biomarkers—such as VEGF—for early detection of dermal and vascular toxicity, supporting safer development of pharmaceuticals and cosmetics. The lab integrates molecular mechanisms with translational applications, aiming to bridge basic science with clinical and pharmaceutical innovation.
Figures are computed from collected data and may differ slightly.
In both permanent and transient ischemic models, carnosine treatment exhibited significant cerebroprotection against histological and functional damage, with wide therapeutic and clinically relevant time windows. Carnosine was well tolerated and exhibited no toxicity. Mechanistic data show that it influences multiple deleterious processes. Taken together, our data suggest that this endogenous pleiotropic dipeptide is a strong candidate for further development as a stroke treatment.
The upregulation of TSP-2 mediated by increased oxidative stress contributes to angiogenesis dysfunction in diabetic BMACs.
Methylglyoxal (MG) is a dicarbonyl compound, the level of which is increased in the blood of diabetes patients. MG is reported to be involved in the development of cerebrovascular complications in diabetes, but the exact mechanisms need to be elucidated. Here, we investigated the possible roles of oxidative stress and mitophagy in MG-induced functional damage in brain endothelial cells (ECs). Treatment of MG significantly altered metabolic stress as observed by the oxygen-consumption rate and ba
Skin is an emerging target tissue in pharmaceutical and cosmetic science. Safety assessment for dermal toxicity is a critical step for development of topically applicable pharmaceutical agents and ingredients in cosmetics. Urgent needs exist to set up toxicity testing methods for dermal safety, and identification of novel biomarkers for pathological cutaneous alteration is highly required. Here we will discuss if vascular endothelial growth factor (VEGF) has a potential as a biomarker for dermal
Open papers in the app to read, cite, and organize with AI.
